A growing community of CEOs and scientists is trying to recast the story of longevity so it's digestible to the drug-making mainstream.January 30, 2023Check out STAT+Sponsored By Mike Reddy for STAT STAT+ | No more 'playing God': How the longevity field is trying to recast its work as serious science Longevity has long been known as a billionaire's sport. A growing community is trying to make it digestible to the drug-making mainstream. By Jason Mast WHO extends public health emergency over Covid but signals end could come soon The global health agency signaled strongly that it believes it may be able to lift the emergency designation in the coming months. By Helen Branswell STAT+ | 'A classic case': A legal expert explains why lawsuits challenging abortion pill restrictions may succeed Carl Tobias, a law professor and former FDA consultant, spoke with STAT about two new lawsuits challenging abortion pill restrictions. By Ed Silverman Alex Hogan/STAT STAT+ | 'Everybody has blood on their hands': A decade-long battle over Medicare Advantage audits is coming to a head A decade-long battle over Medicare Advantage audits is coming to a head as Medicare makes a final determination about industry oversight. By Bob Herman Opinion: Death by missing data: Uncollected racial and ethnic pandemic data will drive inequities for decades to come Missing data on race and ethnicity has been an issue throughout the Covid-19 pandemic. How bad has the problem been? Far beyond bad. By Jennifer W. Tsai and Rohan Khazanchi and Emily Laflamme STAT+ | U.K. lawmakers urge Pfizer not to raise the price of its Covid-19 vaccine Several U.K. lawmakers have asked Pfizer not to raise the price of its Covid-19 vaccine, citing concerns such a move could strain the NHS. By Ed Silverman Adobe Opinion: As it turns 40, the Orphan Drug Act for rare diseases needs a refresh Science has evolved since the Orphan Drug Act became law in 1983. A version 2.0 is needed to help develop therapies for ultrarare diseases. By Emil D. Kakkis STAT+ | FDA names former Oracle executive as new digital health leader The FDA has named Troy Tazbaz, most recently a senior vice president at Oracle, as its new head of digital health. By Lizzy Lawrence STAT+ | Pharma wins a key round in a court battle with hospitals over a drug discount program A federal appeals court ruled drug companies have the right to limit discounts to hospitals that participate in the 340B discount program. By Ed Silverman More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Daily Recap? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments